Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 27, 2014

View Archived Issues

Apceth begins first human trial of genetically modified MSCs in cancer

Experience with tau-binding radiotracer [18F]T-807 accumulates

CHMP issues opinion on ataluren in nonsense mutation DMD

Researchers at Lundbeck present new nAChR PAMs

Endocyte provides update on MAAs for vintafolide and etarfolatide

GSK receives positive CHMP opinion for albiglutide in type 2 diabetes

Novel orexin receptor antagonists designed at Heptares Therapeutics

GSK reports data from phase III study of Tafinlar and Mekinist in melanoma

Canadian group discloses novel BTK inhibitors

hHR21 expression linked to prognosis in patients with colorectal cancer

Japanese researchers divulge new sst2 receptor agonists

Researchers at Esteve have patented novel sigma1R ligands

Crown Bioscience discloses novel kinase inhibitors for cancer

NIBIO, Aeras and Create form global collaboration to advance new mucosal TB vaccines

EMA committee recommends approval of Finox Biotech's biosimilar FSH

Roche's subcutaneous MabThera recommended for approval by CHMP

Lurasidone recommended for treatment of schizophrenia by EMA advisory committee

EMA committee recommends against approval of Nerventra for relapsing-remitting MS

Pacgen to sublicense global rights to antimicrobial peptide to GBC

mRNAs investigated as biomarkers in pancreatic neuroendocrine tumors

EMA committee advises against approval of masitinib for advanced pancreatic cancer

Nihon Medi-Physics launches DatSCAN in Japan

Phase I/II study of OPB-111001 recruiting patients with advanced cancer

Phase I study of novel treatment candidate for alcoholism begins patient recruitment

EMA committee recommends approval of Bayer's riociguat for two forms of pulmonary hypertension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...